Navigation Links
Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology
Date:11/28/2007

cers and pressure sores.

The '648 patent describes a novel, fully biodegradable and resorbable collagen-based material with improved mechanical, physical and functional properties that has application as a wound covering or surgical implant for the purpose of tissue augmentation and repair where mechanical strength is especially desirable. The material may optionally contain drugs and other bioactive substances for local delivery to the site of implantation or tissue defect.

Commenting on receipt of the notices, Dr. Michael Myers, President and CEO said, "The grant of these two patents will both broaden and strengthen the intellectual property covering our core CollaRx platform technology and particularly its applications in wound healing, biosurgery and local drug delivery. Having now secured both European and US patent rights for our advanced wound care product, DermaSIL, we are intent on scaling-up the proprietary manufacturing process and commercializing this product in 2008 through our CollMED Laboratories joint venture in the US and in collaboration with distribution partners in Europe."

About CollaRx(R)

CollaRx is Innocoll's lead technology platform for the site specific, local delivery of a wide variety of drugs with particular emphasis on antibiotics, anesthetics, anti-cancer agents and tissue regeneration proteins and peptides. The CollaRx technology forms the basis of Innocoll's lead product, Gentamicin Surgical Implant, a biodegradable leave-behind implant indicated for the treatment and prevention of surgical site infection in both hard and soft tissue. This product is already approved in 49 countries and is in phase 3 development in the US. Other CollaRx sponge products under clinical development by Innocoll include a CollaRx Bupivacaine Implant for the management of post-operative pain and a topically-applied CollaRx Gentamicin Sponge for the treatment and prevention of diabetic foot infections. Innocoll's CollaRx membrane
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
10. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 (HealthDay News) -- Carving pumpkins and trick-or-treating may ... children to emergency rooms in the United States every ... had the fifth highest number of ER visits involving ... data from the National Electronic Injury Surveillance System. ... head, noted the American Academy of Orthopaedic Surgeons and ...
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. ... all public health tactics known to prevent Ebola transmission ... epidemic, a new study reports. Four practices in ... way, immediately isolating new patients, tracing people potentially exposed ... care workers -- can stop the epidemic within six ...
(Date:10/31/2014)... National Institutes of Health will facilitate communication among ... health research, from diagnosis to treatment. The Research ... the National Institute of Mental Health (NIMH), part ... institute,s RDoC initiative. , The aim of ... of research that translates basic science into clinical ...
(Date:10/31/2014)... are clear differences in the brains of people with ... new research indicates. Scientists at Stanford University ... diagnose this baffling condition and shed light on how ... misdiagnosed or labeled as hypochondriacs. Using three ... [chronic fatigue syndrome] patients, brains diverge from those of ...
(Date:10/31/2014)... (HealthDay News) -- A comparison of two of the ... laparoscopic gastric bypass helped patients shed more excess pounds ... of short-term complications and long-term hospitalizations. Gastric-bypass surgery ... so your body does not absorb all the calories ... of Health. Gastric banding is a type of weight-loss ...
Breaking Medicine News(10 mins):Health News:Halloween at the ER Is No Treat 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 3Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 3Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3
... Mass. -- A subtle mutation affecting the epigenome - a ... lead to an inherited form of mental retardation that affects ... also involves cleft lip or cleft palate, appears to hinge ... offer several potential drug targets. The study, published online ...
... Professor of Public Health and Director of Health Promotion ... evidence that supports relationships seen in adolescents between insulin ... fat and identifies additional potential early markers of insulin ... including fat in muscle cells, blood pressure, physical activity, ...
... HealthDay Reporter , FRIDAY, July 9 (HealthDay News) -- One ... of Avandia, new doubts surfaced Friday on a key trial ... A medical reviewer for the U.S. Food and Drug ... that drugmaker GlaxoSmithKline,s "mishandling" of trial results may have ...
... the 52nd meeting of the American Association of Physicists ... 22, 2010 in Philadelphia, PA, thousands of scientists and ... developments in medical imaging and radiation therapy, examine new ... ethical and regulatory issues that face the field today. ...
... Researchers at Brown University have found that the length of ... doubled during the last 10 years. The study, which will ... the American Geriatrics Society , evaluated hospice use in U.S. ... treatment time has increased from 46 to 93 days. The ...
... HCG True Diet offers ... ... photos and revamped the before and after section of the website. The pictures can be ... taken of a patient before they start the HCG True Diet and after they finish the ...
Cached Medicine News:Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 3Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 2Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 2Health News:FDA Reviewer Questions Results of Key Avandia Trial 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 2Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 3Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 5Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 6Health News:Study: Medicare policy may account for growing length of hospice stays in nursing homes 2Health News:See New HCG Diet Before and After Photos 2
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)( ... the development of oral drug delivery systems, announces ... to discuss the clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes ... Eastern time. Shareholders and other interested ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
... 6 month results from long term durability study presented ... Section meeting of the American Urological Association, ... of innovative therapies in women,s health, announced today that,six ... to,evaluate the long term durability of the Renessa(R) treatment ...
... Community Oncology,Alliance (COA), representing community cancer centers ... & Medicaid Services (CMS),reconsider its decision to ... to,vital anemia-fighting drugs. Effective July 30, 2007, ... oncologists, use of,anemia-fighting drugs, referred to as ...
Cached Medicine Technology:New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 2New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 3Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions 2
... BchiVac V-500 with Vacuum Controller V-800 and water-cooled ... from Model V-500 is a ... most vacuum applications. Applications Ideally ... evaporators Laboratory vacuum source for instruments ...
... Combines BchiVac V-500 with Vacuum Controller V-800 ... Electronic switching mechanism turns V-500 on and off as ... Model V-500 is a powerful PTFE membrane vacuum pump ... Ideally suited for use with up to two ...
... Combines BchiVac V-500 and water-cooled secondary condenser ... is a powerful PTFE membrane vacuum pump ... Applications Ideally suited for use ... Laboratory vacuum source for instruments including ...
... The Universal Vacuum System UVS400 is a ... The UVS400 combines a refrigerated vapor trap ... a single integrated unit. The easy-to-use, wide-mouth ... solvent into single jar for easy disposal. ...
Medicine Products: